DZ Bank Reiterates “Neutral” Rating for Fresenius Medical Care AG & Co. (NYSE:FMS)

Fresenius Medical Care AG & Co. (NYSE:FMS)‘s stock had its “neutral” rating reiterated by investment analysts at DZ Bank in a report issued on Tuesday, May 7th, Borsen Zeitung reports.

FMS has been the topic of a number of other research reports. SunTrust Banks upped their price target on Fresenius Medical Care AG & Co. to $48.00 and gave the stock a “positive” rating in a report on Thursday, February 21st. Royal Bank of Canada reiterated a “neutral” rating on shares of Fresenius Medical Care AG & Co. in a report on Monday, March 18th. Finally, Zacks Investment Research upgraded Fresenius Medical Care AG & Co. from a “sell” rating to a “hold” rating in a report on Tuesday, February 19th. One equities research analyst has rated the stock with a sell rating, six have given a hold rating and four have given a buy rating to the stock. Fresenius Medical Care AG & Co. has an average rating of “Hold” and a consensus price target of $61.33.

Shares of NYSE FMS traded down $0.47 during trading hours on Tuesday, reaching $36.94. The stock had a trading volume of 116,364 shares, compared to its average volume of 244,477. The company has a quick ratio of 0.79, a current ratio of 1.02 and a debt-to-equity ratio of 0.73. The stock has a market cap of $23.37 billion, a PE ratio of 16.27, a price-to-earnings-growth ratio of 2.75 and a beta of 1.40. Fresenius Medical Care AG & Co. has a fifty-two week low of $30.99 and a fifty-two week high of $53.40.

Fresenius Medical Care AG & Co. (NYSE:FMS) last issued its earnings results on Thursday, May 2nd. The company reported $0.59 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.52 by $0.07. The business had revenue of $4.13 billion during the quarter, compared to the consensus estimate of $4.58 billion. Fresenius Medical Care AG & Co. had a return on equity of 10.27% and a net margin of 11.94%. The company’s revenue for the quarter was up 3.9% on a year-over-year basis. During the same period in the prior year, the business posted $0.91 EPS. Sell-side analysts anticipate that Fresenius Medical Care AG & Co. will post 2.36 earnings per share for the current year.

Several institutional investors and hedge funds have recently modified their holdings of FMS. JPMorgan Chase & Co. raised its position in shares of Fresenius Medical Care AG & Co. by 3.4% in the 3rd quarter. JPMorgan Chase & Co. now owns 87,216 shares of the company’s stock worth $4,484,000 after buying an additional 2,854 shares during the period. LPL Financial LLC raised its position in Fresenius Medical Care AG & Co. by 38.3% in the third quarter. LPL Financial LLC now owns 6,278 shares of the company’s stock valued at $323,000 after purchasing an additional 1,739 shares during the period. Virtu Financial LLC purchased a new position in Fresenius Medical Care AG & Co. in the fourth quarter valued at about $339,000. Quadrant Capital Group LLC increased its position in shares of Fresenius Medical Care AG & Co. by 40.0% during the fourth quarter. Quadrant Capital Group LLC now owns 5,294 shares of the company’s stock worth $164,000 after acquiring an additional 1,513 shares during the last quarter. Finally, FNY Investment Advisers LLC purchased a new stake in shares of Fresenius Medical Care AG & Co. during the fourth quarter worth about $583,000. 1.49% of the stock is currently owned by institutional investors and hedge funds.

About Fresenius Medical Care AG & Co.

Fresenius Medical Care AG & Co KGaA, a kidney dialysis company, provides dialysis care and related services, and other health care services in Germany, the United States, and internationally. It offers dialysis treatment and related laboratory and diagnostic services through a network of outpatient dialysis clinics; materials, training, and patient support services comprising clinical monitoring, follow-up assistance, and arranging for delivery of the supplies to the patient's residence; and dialysis services under contract to hospitals in the United States for the hospitalized end-stage renal disease (ESRD) patients and for patients suffering from acute kidney failure.

Further Reading: What are earnings reports?

Analyst Recommendations for Fresenius Medical Care AG & Co. (NYSE:FMS)

Receive News & Ratings for Fresenius Medical Care AG & Co. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fresenius Medical Care AG & Co. and related companies with MarketBeat.com's FREE daily email newsletter.



Leave a Reply